Do not exceed the recommended duration of treatment (3 days).
When administration is carried out using an applicator, care should be taken to avoid soft tissue injury.
Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, to other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.
At the recommended dosage, no undesirable effect is expected. At twice the dosage, a reversible, short term decrease of the intestinal Enterobacteriaceae population can occur, as well as faecal softening, but this is without clinical consequence as the balance of aerobes/anaerobes is not affected.
A greenish coloration of the faeces is sometimes observed, but this is reversible when the treatment is discontinued.
Concurrent administration of oral preparations which contain a high proportion of divalent cations may reduce marbofloxacin activity.
At four times the recommend dosage, a marked, reversible decrease in the intestinal Enterobacteriaceae population was observed. Diarrhoea can occur at higher dosages, as is known to occur for other oral antibiotics administered to neonatal animals. Further administration of marbofloxacin must be stopped and symptomatic treatment instituted.
Operator warning
People with known hypersensitivity to fluoroquinolones should avoid using this product. Wash hands after use.
Withdrawal periods
Meat: 6 days.
The product is not indicated for use in lactating animals.